Foley Hoag Advises CutisPharma in Sale to NovaQuest Capital Management
March 27, 2018
Foley Hoag LLP recently represented specialty pharmaceutical company CutisPharma, Inc. in its sale to NovaQuest Capital Management, L.L.C., a leading investor of life sciences and healthcare companies.
Founded in 1998, Wilmington, Mass.-based CutisPharma develops and commercializes compounding kits that help patients who are unable to swallow conventional oral dosage forms, such as tablets and capsules, and whose needs are not served by commercially available therapies. The company’s portfolio of kits is utilized in thousands of retail and hospital pharmacies across the United States.
NovaQuest was formed in 2000 to provide strategic capital to life sciences and healthcare companies through its biopharma and private equity strategies. The acquisition of CutisPharma is considered an excellent fit with NovaQuest’s philosophy of providing strategic capital to businesses that reduce the cost of care, meet unmet medical need, increase efficacy, and improve quality of life.
Foley Hoag attorneys Daniel Clevenger, Joseph Basile, Jonathan Romiti, Yashreeka Huq, Colin Zick, Nicola Lemay, Nicholas Romanos, Jennifer Audeh, Mai Zymaris and paralegal Cliff Esher advised CutisPharma in the transaction.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.